secwatch.observer — SEC 8-K summary
======================================

Issuer:     Damora Therapeutics, Inc. (DMRA)
CIK:        0001800315
Form:       8-K
Filed at:   2022-06-17T23:59:59+00:00
Accession:  0000950170-22-011770
Event type: other
Sentiment:  neutral
Materiality: 0.10
Item codes: 5.07
LLM model:  deepseek-v4-flash:cloud@v2

Galecto stockholders elect two Class II directors and ratify auditor at 2022 annual meeting
--------------------------------------------------------------------------------

- Carl Goldfischer, M.D. elected with 11,025,408 votes for; David Shapiro, M.D. with 11,050,440 votes for.
- Ratification of EY Godkendt Revisionspartnerselskab as independent auditor for FY2022: 15,589,293 for, 33,022 against.
- 15,647,815 shares represented at meeting out of 25,261,832 entitled to vote; 3,360,631 broker non-votes on director election.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1800315/000095017022011770/0000950170-22-011770-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1800315/000095017022011770/glto-20220614.htm
  HTML page:      https://secwatch.observer/filing/0000950170-22-011770

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer